Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Individuals diagnosed with rare diseases had higher COVID-19 rates than people who did not have them. As per a study analysing health records of 62.5 million people in England, there were significant differences in infections recorded across ethnic groups and individual rare diseases.

Published in Scientific Reports recently, the study analysed 406 rare diseases with the help of healthcare records from the National Health Service (NHS) in England.

Of the 62.5 million people included in the analysis, around 1.05 million, or 1.7%, had at least one of the 406 rare diseases.

COVID-19 infections were reported in around 32.8% of people with a rare disease, compared with 29% of those without one. Even though the difference between the two figures is not far from each other, it makes us stop and think.

According to the study researchers, the findings provide a country-wide picture of rare disease rates and incidence of COVID-19 infections across various ethnic groups.

COVID-19 Infection Rates Differed Across Rare Diseases

The study found that COVID-19 infection rates differed significantly depending on the rare disease. Among the 25 most common rare diseases, infection rates ranged from 24.6% to 41.2%.

Four conditions had recorded infection rates below 30%: congenital laryngomalacia, at 24.6%; retinopathy of prematurity, at 26.5%; polymyalgia rheumatica, at 27.1%; and infantile apnoea, at 29.9%. The remaining 21 conditions had recorded infection rates between 30% and 50%.

These differences highlight an important point that people with rare diseases should not be treated as one uniform group, especially when it comes to their COVID experience.

However, the study did not establish that every person with a rare disease had a higher risk of contracting the virus, nor did it show that rare diseases necessarily led to more severe COVID-19.

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

Infection Rates Differed By Ethnicity

The researchers also identified differences in COVID-19 infection rates among ethnic groups within the rare disease occurrence.

The highest rates were observed among people classified as White British, at 33.7%, and those in the broader White category used by the Office for National Statistics (ONS), at 33.5%.

Lower rates were recorded among several other groups, including Black African people, at 23.8%; Gypsy or Irish Traveller people, at 24.1%; Bangladeshi people, at 27.2%; and Pakistani people, at 27.7%.

The researchers said that this pattern was different from trends in the general population, where ethnic minority groups experienced an uneven burden of COVID-19.

Rare Diseases Varied Across Ethnic Groups

Apart from COVID-19 infection, the study mapped 406 rare diseases across various ethnic groups. The researchers found variations in how frequently each condition was recorded.

Some of these differences became clearer when broad ethnic categories were divided into more specific groups. For example, discoid lupus erythematosus was more prevalent among Black Caribbean people than among Black African people.

The researchers also found that polymyalgia rheumatica was more prevalent among White people than Asian or Asian British and Black or Black British populations.

Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees

How Was The Study Conducted?

The researchers carried out a cross-sectional analysis using NHS England’s Secure Data Environment, linking primary care, hospital and mortality records for people alive on July 31, 2023.

They estimated the prevalence of 406 rare diseases and examined COVID-19 infections across the overall population, individual rare diseases and ethnic groups. The analysis used both six ONS ethnic categories and 19 more detailed NHS ethnicity classifications.

The study’s large population base allowed the researchers to examine conditions that can be difficult to investigate because each rare disease affects relatively few people.

The researchers said the national estimates provide a baseline for understanding rare disease rates and COVID-19 cases across different populations in England. The findings may help inform future research and support efforts towards earlier diagnosis and better healthcare.

Nearly 94% of tuberculosis (TB) patients in an Indian study conducted in Bengaluru reported anxiety symptoms, while 77.3% showed signs of depression. The findings focus on the mental health toll that comes with TB. It also sheds light on the need to include psychological support in routine treatment of tuberculosis.

The cross-sectional study, conducted with 66 adults at the Yeshwanthpur Tuberculosis Unit in Bengaluru, found that 56.1% had moderate to severe anxiety symptoms, while 46.9% had moderate to severe depressive symptoms. Nearly half of the participants experienced symptoms of both conditions.

The study was conducted by Dr. Pavithra Cheluvaraj, Dr. Vishnu C. Sudhakaran, Dr. Babitha Rajan and Anjana Sasikumar Nair from the Department of Community Medicine at Ramaiah Medical College.

The researchers examined the patients using the Patient Health Questionnaire-9 (PHQ-9) and the Generalised Anxiety Disorder-7 (GAD-7) scales.

Why Are TB Patients May Experience Anxiety And Depression?

Stigma linked with TB, fear of transmitting the infection to family members and existing health conditions may contribute to anxiety and depression among patients, Dr. Pavithra told Bangalore Mirror.

TB treatment can also entail a prolonged course of medication and regular follow-up. Psychological distress may make it harder for patients to continue treatment or seek timely care.

According to Dr. Pavithra, anxiety and depression if left untreated could affect the course of TB treatment. Patients experiencing psychological distress may delay starting treatment or stop taking their medication, which could compromising recovery and increasing the risk of drug resistance.

“If there is delay in diagnosis or treatment, the person can spread the disease,” she said.

Also read: You May Be Carrying TB, And Not Know Until It Gets Worse

How Was Mental Health Assessed In The Study?

The researchers used two standardised screening tools to assess symptoms of depression and anxiety.

The PHQ-9 measures depressive symptoms, while the GAD-7 tests for symptoms of anxiety. The study found that 51 of the 66 participants had symptoms linked with depression, and 62 had symptoms that indicated anxiety.

Moderate to severe symptoms were found in 31 participants for depression and 37 for anxiety. These screening results indicate the need for further clinical assessment. The findings are merely observations and they do not mean that every participant had a confirmed psychiatric diagnosis of anxiety and depression.

Additionally, the study was based on 66 adults in one tuberculosis unit in Bengaluru, so its findings cannot represent all TB patients in India.

But the high percentage of participants who reported symptoms of anxiety and depression suggest that there is need for better integration of mental health screening into TB treatment.

The researchers recommended routine screening for depression and anxiety when patients are diagnosed with TB and during follow-up visits. They also called for counselling and referrals for patients with more severe symptoms.

They say that identifying psychological distress early may help doctors connect patients with appropriate support while they receive treatment for the infection.

TB Is A Global Health Crisis

Even though this study is based on a small sample, it speaks about the long-term effects of the disease on mental health. TB is a global health crisis, which means this study warrants further investigation and action.

According to the WHO’s Global Tuberculosis Report 2025, in 2024, more than ten million people across the globe developed TB while more than 1.2 million lost their lives to the disease.

Currently, India bears the lion's share of TB burden compared to other countries. Uneven access to drug-resistant TB treatment, financial hardships, stigma, prolonged treatment are some of the factors that may contribute to deteriorating mental health of TB patients.

GLP-1 medications, widely prescribed for diabetes and weight loss, may also be associated with a lower risk of serious complications after surgery, a new study suggests.

The study, involving more than 2 million adults undergoing surgery, found that people taking GLP-1 medications had lower rates of major cardiovascular complications and postoperative infections than those not taking the drugs. Researchers from the University of Texas Health Houston presented the findings at the Anesthesiology 2026 annual meeting.

"GLP-1 medications have become part of everyday care for many people with diabetes or obesity, but physicians still need more evidence about how these drugs affect patients around the time of surgery," said lead author Josephine Tolan, an anesthesiologist at the Center for Outcomes Research, Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School at UTHealth Houston.

Tolan added that although the results are encouraging, more research is needed to determine if the medications themselves are driving these benefits and how best to manage them before and after surgery.

What Are The Key Findings

Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

Researchers analyzed data from the Epic Cosmos database, a de-identified electronic health record database covering more than 1,700 hospitals and 40,000 clinics.

The study included US adults aged 18 and older who underwent elective surgeries lasting more than 60 minutes and stayed in the hospital for at least 24 hours after surgery between January 2016 and December 2024. Of the 2,028,601 patients included, 145,610, or about 7%, were taking GLP-1 medications.

After matching GLP-1 users with similar patients who were not taking the drugs, researchers found that GLP-1 use was associated with:

• 11% lower odds of major cardiovascular complications, including heart attack, heart injury, stroke or death.
• 8% lower odds of postoperative infections, including surgical site infections, urinary tract infections, pneumonia and sepsis.

How Might GLP-1 Drugs Affect Surgical Outcomes?

Read More: GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study

Previous research has shown that GLP-1 medications can lower the risk of cardiovascular problems in some patients. However, their effects during and after surgery remain less clear.

Surgery places stress on the body, can trigger inflammation and may cause changes in blood pressure, blood sugar and circulation, potentially increasing the risk of cardiovascular complications and infections, the researchers explained.

Further, they suggest that GLP-1 medications may be associated with fewer cardiovascular complications because they support weight loss, improve blood pressure and blood sugar control, reduce inflammation and may protect heart muscle during periods of stress.

These medications may also help reduce infection risk by improving blood sugar control. High blood sugar can weaken the body's immune response, making it harder to fight infections.

GLP-1 Drugs And Cardiovascular Health

READ: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?

Research has found that people taking GLP-1 medications to treat diabetes, overweight or obesity have fewer major cardiovascular events, like heart attack or stroke, compared to people not taking GLP-1 medications.

In fact, the American College of Cardiology now recommends GLP-1 drugs as a way to reduce cardiovascular disease risk through weight loss.

When weight decreases, so does blood pressure, inflammation, LDL (bad) cholesterol and triglycerides, and protective factors like good (HDL) cholesterol increase. In other words, overweight or obese individuals who are prescribed a GLP-1 for weight loss may experience positive changes to their heart health, especially if they are at risk of heart disease.